Prognostic Factors for Disease-Free Survival of Ethnic Chinese Patients with Ocularmelanoma.
Xi Nan Shang,Si Ming Li,Zhihong Chi,Lu Si,Chuan Liang Cui,Li,Xuan Wang,Bin Lian,Bi Xia Tang,Jun Guo
DOI: https://doi.org/10.1200/jco.2014.32.15_suppl.e20016
IF: 45.3
2014-01-01
Journal of Clinical Oncology
Abstract:e20016 Background: Ocluar melanoma is worthy of unique concerns because of its noticeable differences with cutaneous melanoma. The knowledge on clinical outcome in Asian patients is also limit. There is no standard recommendation in surgery for primary ocular melanoma and adjuvant treatment after surgery. The aim of this study is to evaluate the prognostic factors for disease-free survival (DFS) after surgery in Chinese ocular melanoma. Methods: Clinical data from January 2006 to April 2013 including age at diagnosis, gender, anatomic location (uveal or conjunctival), stage (I, II, III), type of surgery, adjuvant therapy, and DFS of patients with ocular melanoma were retrieved from Beijing Cancer Hospital’s database. Univariate and multivariate analyses of factors associated with DFS were respectively performed by Kaplan-Meier method and Cox proportional hazard model. Results: A total of 95 patients (61 males, 34 females) with ocular melanoma were evaluated. 53.7% had uveal melanoma and46.3% had conjunctival melanoma. Stages I, II and III disease were present in 33.7%, 52.6%, and 13.7%, respectively. The 3-year DFS rate and the median DFS time of all 95 patients were 47.5% and 35 months, respectively. Three-year DFS rate of patients with diseases of stage I, II, III were 57.9%, 48.2%, 8.5%, respectively. Patients who received high-dose interferon-α2b (HDI) as adjuvant therapy had significantly higher 3-year DFS ratesthan those who did not receive adjuvant therapy or received chemotherapy. Multivariate analysis indicated that the anatomic location, stage, and adjuvant therapy were significant predictive factors for DFS. Conclusions: The clinical stage, anatomic location and adjuvant therapy are independent prognostic factors for DFS in Chinese ocular melanoma patients.